Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

t Onyx Pharmaceuticals, Inc.  "This program is a highly innovative approach to industry-academia collaboration, bringing together leaders from the myeloma research community in the service of a common goal: driving an integrated, personalized approach to the development and delivery of medicines to patients."

Company-sponsored carfilzomib and oprozomib abstracts:

A Phase 1, Dose-Escalation Study (CHAMPION-1) Investigating Weekly Carfilzomib in Combination with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

  • Dr. James R. Berenson, Institute for Myeloma & Bone Cancer Research
  • Saturday, December 7, 5:30 pm - 7:30 pm CT, Hall G
  • Poster presentation: Myeloma: Therapy, excluding Transplantation: Poster I
  • Abstract # 1934

Association of Treatment Induced Peripheral Neuropathy (TIPN) with Treatment Patterns and Outcomes in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM)

  • Dr. Thomas Martin, University of California, San Francisco
  • Saturday, December 7, 5:30 pm - 7:30 pm CT, Hall G
  • Poster presentation: Health Services and Outcomes Research: Poster I
  • Abstract # 1750

Relationship of Serum Free Light Chain Reduction to Best Overall Response in Phase 2 Single-Agent and Combination Studies of Carfilzomib in Patients with Relapsed or Relapsed and/or Refractory Multiple Myeloma

  • Dr. Ravi Vij, Washington University School of Medicine, St. Louis, MO
  • Saturday, December 7, 5:30 pm - 7:30 pm CT, Hall G
  • Poster presentation: Myeloma: Therapy, excluding Transplantation: Poster I
  • Abstract # 1965

Clinical Profile of Single-Agent Modified-Rele
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... 12, 2014 The DNA Microarray ... 2013, and is expected to grow at a ... Browse through the TOC of the DNA Microarray ... and segments, with help of various tables and ... DNA Microarray market consists of instrument, consumables, and ...
(Date:12/13/2014)... (PRWEB) December 13, 2014 QuickSTAT is ... network and Cold Chain capabilities, and is delighted to ... Paris, France, to serve Life Science clients in the ... with a controlled-ambient warehouse, will provide 24/7 transportation and ... and investigational drugs, patient-clinical specimens, API, following IATA rules ...
(Date:12/13/2014)... RARITAN, N.J. and SAN ANTONIO ... Development, LLC (Janssen) today announced the presentation of data ... the Phase 3 EPO-ANE-3010 study evaluating epoetin alfa plus ... treat anemia in patients with metastatic breast cancer receiving ... primary objective, which was to rule out a 15 ...
(Date:12/12/2014)... Electronic Data Interchange (EDI) has helped evolve ... chain management to depend from paper based to ... with the use of EDI such as cost ... improve the acceptance of this technology in the ... and 107 figures spread through 210 pages and ...
Breaking Biology Technology:DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 2DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 4Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 2The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 3The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 4
... division of Nycomed,US Inc., today announced the FDA ... formulation compares to Taro,s Referenced Listed Drug (RLD),and ... # 0168-0133-15), 30g tubes,(NDC # 0168-0133-30) and 45g ... Clotrimazole Cream is another illustration of,Fougera,s robust product ...
... HAYWARD, Calif., Sept. 12 Acologix, Inc., a ... two,preclinical studies demonstrating that AC-100, its therapeutic product,candidate ... bone and,dental cells, promotes cartilage regeneration in large ... Catherine A. Middleton-Hardie on September,13, 2008 at the ...
... -- Simcere Pharmaceutical,Group (NYSE: SCR ), a ... manufacturer of the patented anti-cancer biotech,product Endu in ... Zhou,and Mr. Xiaojin Yin to Executive Vice President ... Mr. Qingsen Li to the newly created,position of ...
Cached Biology Technology:Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting 2Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting 3Simcere Pharmaceutical Group Announces Two Senior Promotions and Appointment of New Vice President of Human Resources 2
(Date:11/21/2014)... YORK , Nov. 19, 2014  Earlier this ... at New York College, and one of the most ... biosensor signals that are transmitted from Smartphones to third ... were Smartphones and has one of the earliest known ... discussing its usage in the military, child care, elder ...
(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
(Date:11/11/2014)...  Forensicon, Inc., a Chicago -based ... the promotion of Yaniv Schiff from Senior ... Schiff,s new role as Director, he will lead company ... examiners and provide leadership within the company,s digital forensics ... Schiff joined Forensicon in 2006 ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... hiding in the human immune system. Accessing it, however, ... roles that the immune system plays can mask the ... issues. Now, research led by scientists from the California ... generation of microchips developed by the team can quickly ...
... find happy guys significantly less sexually attractive than swaggering or ... study that helps to explain the enduring allure of "bad ... which may cause men to smile less on dates, and ... dramatic gender differences in how men and women rank the ...
... Ariz. The International Institute for Species Exploration at ... around the world scientists responsible for species exploration ... 10 new species described in 2010. The May 23 ... Carolus Linnaeus, the Swedish botanist who was responsible for ...
Cached Biology News:Improving health assessments with a single cell 2Improving health assessments with a single cell 3Happy guys finish last, says new study on sexual attractiveness 2Happy guys finish last, says new study on sexual attractiveness 3Scientists list top 10 new species 2Scientists list top 10 new species 3Scientists list top 10 new species 4Scientists list top 10 new species 5Scientists list top 10 new species 6Scientists list top 10 new species 7
... Agencourt AMPure is a magnetic ... requires no sample transfer, centrifugation ... purifies small and large PCR ... 384-well microplates. Agencourt AMPure can ...
... Agencourt AMPure is a ... that requires no sample transfer, ... efficiently purifies small and large ... or 384-well microplates. Agencourt AMPure ...
... designed for the fast and simple integration ... any position (for the generation of transgenic ... designed to allow neomycin / kanamycin selection ... a prokaryotic promoter (gb2) for expression of ...
Includes a choice of any 3 EasySep mouse selection kits and EasySep magnet...
Biology Products: